While this changes did not impact potency for this particular molecule, the large lot-to-lot variably in charge variant distribution raised significant process regularity issues

While this changes did not impact potency for this particular molecule, the large lot-to-lot variably in charge variant distribution raised significant process regularity issues. While glycation can form in the bioreactor, it can also form after harvest as long as sufficient sugars is present. effect to biological activity and stability of the molecule, with no detrimental effects observed. Incorporating this knowledge into the assessments of candidate drugs could allow for the selection of molecules less susceptible to this product degradation pathway, allowing for greater developing flexibility. This process of identifying and eliminating reactive lysine AV412 residues could be useful in the design of drug candidates with improved charge state stability, across a range of modalities. KEYWORDS: Glycation, stability, charge variants, process intermediate ABSTRACT Open in a separate window Shows Observed a shift in the charged species when holding clarified cell tradition fluid The cause of this shift has been identified as changes in glycation Three conserved, solvent accessible, lysines were identified as glycation sites Stability was improved by replacing these lysine residues with arginine Removing glycation sites in drug candidates can result in more stable molecules Introduction During the developing of restorative monoclonal antibodies (mAbs) these proteins are susceptible to a host of enzymatic and non-enzymatic modifications. Potential modifications include glycosylation, N-terminal glutamine cyclization, aspartate isomerization, C-terminal lysine processing, deamidation, oxidation, glycation, peptide relationship cleavage, and disulfide AV412 relationship reduction and formation [1]. These modifications happen in the production bioreactor during protein manifestation [2] but modifications can also happen under conditions experienced during antibody purification [3], and storage under final formulation conditions [4,5]. Regulatory companies recognize the heterogeneous nature of biological therapeutics and have issued guidance on characterizing and monitoring post-translational modifications. According to The International Council for Harmonization of Complex Requirements for Pharmaceuticals for Human being Use (ICH) Q6B The manufacturer should define the pattern of heterogeneity of the desired product and demonstrate regularity with that of the lots used in preclinical and medical studies.[6] One fashion to demonstrate product and course of action consistency is through monitoring the charge variant distribution through capillary isoelectric focusing (cIEF) as many of the modifications described above effect the isoelectric point of the protein variant. Glycation is a post-translational changes that has the potential to significantly alter the charge variant distribution, resulting in lot-to-lot inconsistencies, in part because it is definitely difficult to control. Glycation is the nonenzymatic addition of a sugars molecule to a free amino group on a protein. The reaction can occur both in-vivo [7] and in-vitro [8] and the degree of glycation can be impacted by cell tradition conditions, such as glucose levels [8] and the imply residence time of excreted protein in the cell tradition media. Previous studies have used enrichment techniques to independent the mAbs glycated during the cell tradition process and used this material to identify glycation sites. Quan et al. [9] utilized this method of enrichment to identify eight reactive lysines that appeared to have a different susceptibility to glycation. Here, we were able to Rabbit Polyclonal to BEGIN determine glycation sites and relative abundance without the need to enrich the sample. This allows for an unbiased comparison between samples and allows for the identification of those sites that are glycated over the course of clarified cell tradition fluid hold instances. In another study, Miller et al. [10] looked at a mAb that was highly reactive to glycation, with upwards of 80% of the molecules containing a minumum of one glycation site upon incubation in the presence of glucose. They identified that the bulk of the glycation was happening at a single site in the Complementarity-determining region. While this changes did not effect potency for this particular molecule, the large lot-to-lot variably in charge variant distribution raised significant process regularity issues. While glycation can form in the bioreactor, it can also form after harvest as long as adequate sugars is present. Glycation can also happen outside the bioreactor so long as there is adequate reducing sugars present. One example would be drug product formulations that contain sucrose which could hydrolyze into its reducing constituents (glucose and fructose). For this reason, Fischer et al. explored the composition of the drug product formulation on mAb glycation levels[11]. They found products stored in sucrose comprising formulations to be at no higher risk for protein glycation. Another source of variability in overall glycation levels regularly encountered in the developing of monoclonal antibodies is the amount of time between harvest and execution of the capture chromatography step and the conditions AV412 under which this material.